RareResearch.AI
← Back to atlas

P292S

Category 3/4 — Most DruggableLikely pathogenicCytoplasmic · predictedEditorial
ProlineSerine at position 292 · N-terminal cytoplasmic domain (87-313) · WFS1 (Wolframin)

Proline → Serine at position 292 in wolframin's N-terminal cytoplasmic domain. ClinVar Likely pathogenic for classical Wolfram syndrome 1. AlphaMissense 0.957, DynaMut2 ΔΔG -0.74 kcal/mol (destabilising). Critically, pLDDT at this position is 54 — just above the Category 5 IDR threshold but in a low-confidence region.

Interactive 3D Structure

Wild-type reference
Wild-type P292 — hydrogen bond to I296
Fullscreen ↗
DynaMut2 mutant · P292S
Mutant S292 — van der waals contact to H294 lost
Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

1 lost0 gained4 preserved
Interaction typeWild-type partnerMutant partnerStatus
Hydrogen bondI296I296Preserved
Polar contactH294H294Preserved
Polar contactA295A295Preserved
Polar contactI296I296Preserved
Van der WaalsH294Lost

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG
-0.74kcal/mol
Destabilising — mild
AlphaMissense
0.957
LPath
AlphaFold pLDDT
54
model confidence
Schema
Cat 3/4
Category 3/4 — Most Druggable
ΔΔG confidence: Reduced confidence · Cytoplasmic
  • pLDDT 54.16 below 70

The underlying AlphaFold model has pLDDT below 70 at this position, so the structure the stability calculation was run on is itself uncertain.

Do not rank this value against a variant from a different region on ΔΔG alone.

Clinical Evidence

ClinVar classificationLikely pathogenic
Review statuscriteria provided, single submitter
Associated conditionsWolfram syndrome 1
InheritanceAutosomal recessive Wolfram syndrome 1 phenotype documented in ClinVar.
Population frequency (gnomAD v4)Ultra-rare · AF 0.0011%
cDNA changec.874C>T
ClinVar accessionVCV003377398
Last evaluated2022/03/31 00:00

Observed at very low frequency in gnomAD.

Classified for1★ unverified submission

ClinVar classifies this variant as Likely pathogenic for Wolfram syndrome (classic) (autosomal recessive, OMIM 222300). Classic Wolfram syndrome is recessive: a single copy does not produce it, and this classification says nothing about a carrier's own risk.

  • Wolfram syndrome (classic)autosomal recessive · OMIM 222300submitted as: Wolfram syndrome 1
  • This rests on a single submitter (1★). Treat the conditions above as submitted, not as documented phenotypes.
  • Phenotype scope is interpretation of submitted records. The computed values on this card (AlphaMissense, DynaMut2 ΔΔG, pLDDT) are measurements of the model, not of a patient.
  • Presentation cannot be generalised from neighbouring variants: one nucleotide over can present very differently. Structural similarity supports a mechanistic hypothesis, never a phenotype claim.

Review status: 1★ single submitter. ClinVar "conditions" is the union of all submissions; 0–1★ entries are submitted conditions, not documented phenotypes.

Population frequency
Global (all ancestries)
AF 0.0011% · 16 / 1,461,800 alleles
Homozygotes
0
Highest-frequency population
European (non-Finnish) · AF 0.0014%

Highest in European (non-Finnish): AF 0.0014% (16 of 1,111,968 alleles), in line with the global figure.

No homozygotes reported in gnomAD v4. For a recessive allele this is expected and is not, on its own, evidence either way.

Ancestry groupAllele freq.AC / ANHom.Carrier est.
European (non-Finnish)0.0014%16 / 1,111,9680~1 in 34750

Source: gnomAD r4, retrieved 2026-08-21. Values are allele frequencies. The carrier estimate is derived from the allele frequency (Hardy-Weinberg, ~2·AF) and is an approximation, not a published figure — where a published carrier frequency exists it outranks this column and is cited on the card.

Structural Context

Position 292 sits in wolframin's N-terminal cytoplasmic domain. The AlphaFold model places P292 within 5 Å of LEU293 (2.5 Å), TYR291 (2.5 Å), VAL288 (3.6 Å), HIS294 (4.4 Å), and ALA295 (4.7 Å). The local environment is mixed hydrophobic-polar.

The wild-type proline at 292 likely plays a deliberate structural role — proline residues in cytoplasmic domains often define loop boundaries or contribute backbone constraints that orient the domain for partner binding. Replacing it with serine removes that backbone constraint and adds a hydroxyl group with H-bond capacity.

The |ΔΔG| of 0.74 kcal/mol is interpretively complicated by the pLDDT of 54. DynaMut2 assumes a meaningful input structure; at pLDDT 54 the local AlphaFold prediction has lower confidence than the typical Atlas variant. The ΔΔG should be read as a directional indicator rather than a quantitative claim. AlphaMissense's 0.957 score is independently supportive — the substitution is pathogenic even if the structural mechanism is partially obscured by model uncertainty.

ClinVar Likely Pathogenic for classical Wolfram syndrome 1 confirms the variant's clinical relevance.

Amino-acid chemistry
Proline (P) → Serine (S) — a rigid, helix-breaking residue replaced by a small polar hydroxyl-bearing residue. The substitution removes the proline's backbone constraint and introduces hydrogen-bonding capacity.
Position in the protein
N-terminal cytoplasmic domain · position 292 sits in a region with relatively low AlphaFold confidence (pLDDT 54), just above the Cat 5 IDR threshold of 50. Interpret structural predictions here with caution.

Druggability Assessment

Category 3/4 — Most Druggable (with caveat). |ΔΔG| = 0.74 kcal/mol below the fold-integrity threshold. AlphaMissense 0.957 confirms pathogenic signal. However, pLDDT of 54 means the structural details deserve experimental validation before drug design proceeds.

The mechanism is removal of a deliberate proline backbone constraint plus introduction of a polar hydroxyl. Therapeutic strategy: a small molecule that stabilizes the wild-type backbone geometry around the position 292 loop region. Pharmacological chaperone screening is the safer initial approach given the structural confidence caveat.

Why this matters

P292S sits in a borderline-confidence region of the AlphaFold model. The Atlas captures this with the pLDDT score; pre-atlas drug discovery would have either treated the variant at full structural confidence (overconfident) or ignored it entirely (under-utilizing the AlphaMissense signal). The dual-metric framing makes the appropriate caution visible — proceed with chaperone screening, validate experimentally, then proceed to docking once the structural geometry is confirmed.
Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the P292S PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download P292S PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.

UniProt Domain Annotation

Chain1890 · Wolframin
Region1321 · Interaction with ATP6V1A
Natural variant292292 · in WFS1; dbSNP:rs746923441